Jan A. Burger, MD, PhD, on Long-Term Outcomes with Ibrutinib in High-Risk Patients with CLL/SLL

News
Video

An integrated analysis of 2 phase 3 studies with up to 6.5 years of follow-up reported the outcomes of first-line ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma and high-risk genomic features.

An integrated analysis of 2 phase 3 studies with up to 6.5 years of follow-up, presented at the 2020 American Society of Hematology (ASH) Annual Meeting, reported the outcomes of first-line ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) and high-risk genomic features.

The findings from the phase RESONATE-2 and iLLUMINATE studies confirmed significant progression-free survival (PFS) and overall response rate (ORR) benefits with ibrutinib with or without obinutuzumab (Gazyva), versus chlorambucil with or without obinutuzumab, and demonstrated similar PFS and ORR for patients treated with ibrutinib with or without high-risk genomic features.

In an interview with CancerNetwork®, Jan A. Burger, MD, PhD, of the Department of Leukemia in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, spoke about what he believes is most important for providers to take away from these study results.

Transcription:

I think the take home message from this abstract is it gives us reassurance now with longer follow up from these studies that we really need to push in the direction of treating higher risk patients with the new agents. It gives us reassurance that this trend, which is already happening as these widely prescribed nowadays for CLL patients – at least in the US and in Europe – it gives us reassurance that this is the right trend and that the benefit for the high-risk patients from these new agents is ongoing and is durable.

Reference:

Burger JA, Robak T, Demirkan F, et al. Outcomes of First-Line Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and High-Risk Genomic Features with up to 6.5 Years Follow-up: Integrated Analysis of Two Phase 3 Studies (RESONATE-2 and iLLUMINATE). Presented at the 2020 American Society of Hematology (ASH) Annual Meeting. Poster 2220.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Related Content